Synthetic Immodulin Peptides for IGF-Independent Monocyte Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not effectively utilized insulin-like growth factor binding protein (IGFBP)-derived peptides to stimulate the differentiation of specific mammalian cell lineages, particularly monocyte lineages, and their effects are often dependent on insulin-like growth factors (IGFs).
Innovation Solution
Synthetic immodulin peptides, derived from less than 10% of IGFBP amino acid sequences, are used to promote IGF-independent differentiation of cell lineages by interacting with cellular machinery and altering transcriptional sets, with enhanced potency through C-terminal extensions and covalent attachment to small molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full-length classical IGFBPs are used to deliver IGFs, then IGF binding and delivery function is achieved, but the ability to induce IGF-independent cellular differentiation is limited
Solution Approach 1:
The patent segments the IGFBP protein into smaller peptide fragments (2-10 amino acids) that retain specific biological activities. By dividing the full-length IGFBP into modular peptide units, the invention uncovers sequences that can induce cellular differentiation independently of IGF binding, thus resolving the contradiction between maintaining IGF delivery function and enabling IGF-independent differentiation.
Solution Approach 2:
The patent extracts specific amino acid sequences from the IGFBP protein that are responsible for IGF-independent differentiation effects. By isolating these functional domains (such as the C-terminal regions), the invention creates peptides that can selectively induce monocyte and other cell lineage differentiation without requiring full-length IGFBP structure or IGF binding capability.
2Adaptability or versatility
If short IGFBP-derived peptides are used, then IGF-independent differentiation effects are achieved, but peptide stability and binding properties are reduced
Solution Approach 1:
The patent creates composite peptide structures by combining short IGFBP-derived sequences with stabilizing modifications. These may include cyclization, incorporation of non-natural amino acids, or conjugation to carrier molecules, which enhance the stability and binding properties of the otherwise labile short peptides while preserving their differentiation-inducing activity.
Solution Approach 2:
The patent modifies physical and chemical parameters of the IGFBP-derived peptides to improve stability. This includes optimizing amino acid composition, adjusting peptide concentration, modifying pH conditions, or incorporating protective groups that enhance peptide half-life and binding affinity without compromising the IGF-independent differentiation effect.
3Productivity
If extended immodulin peptide sequences are used, then differentiation potency is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent divides extended immodulin sequences into modular repeating units or domains that can be synthesized independently and then assembled. This segmentation approach maintains the high differentiation potency of extended sequences while simplifying manufacturing by enabling modular production and quality control of each segment before final assembly.
Data Source
AI summary
This invention provides synthetic immodulin peptides and related compositions and methods. The peptides of this invention exhibit new and surprising biological activities, such as the expansion of specified differentiated mammalian lineages from precursor cell populations which play important roles in post-apoptotic clearance, autoimmunity, targeted vaccination, cancer and trauma, by contacting mammalian cells with the synthetic peptides. Furthermore, the peptides of the invention can be made significantly more potent by each of a series of modifications described in the invention, including a carboxyterminal tripeptide extension to the canonical immodulin core sequence, other peptide extensions with kinase-inhibiting and other domains, substitution with modified amino acids, conjugation to certain bioactive small molecules, complexation to metals or glycosaminoglycans, and co-administration with helper molecules. The invention also teaches compositions and methods for enhancing previously disclosed uses of immodulin peptides to boost the efficacy of immodulin peptides in trauma, immune imbalance, cancer and other medically relevant conditions.